<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite treatment with intensive immunosuppressive drug regimens, the prognosis of patients suffering from severe progressive <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> like <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo> (NS), and <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease is poor </plain></SENT>
<SENT sid="1" pm="."><plain>Side effects (<z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> and <z:mp ids='MP_0002018'>malignant tumors</z:mp>) often occur </plain></SENT>
<SENT sid="2" pm="."><plain>In the present trial, 35 patients suffering from <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> (SLE, n = 21; NS, n = 10; and <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, n = 4) were treated for 3.7 +/- 2.0 years with 2.5 +/- 0.6 mg <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>/kg body weight/day in addition to <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> alone or in combination with <z:chebi fb="2" ids="2948">azathioprine</z:chebi> and/or <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>In active stages of the diseases with extremely high concentrations of anti-ds-DNA-antibodies, <z:hpo ids='HP_0003493'>antinuclear antibodies</z:hpo>, circulating immunocomplexes, and reduced complement concentrations, therapeutic plasma exchange (TPE) has been applied </plain></SENT>
<SENT sid="4" pm="."><plain>Compared with previous treatment modalities, significantly (p &lt; 0.05) more effective and rapid reductions of the antibodies were reached </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical disorders improved within 1-6 weeks </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients reported increased performance and a better quality of life </plain></SENT>
<SENT sid="7" pm="."><plain>After 1-12 months, the previously required doses of immunosuppressive drugs and the frequency of TPE could be reduced by 40-100% </plain></SENT>
<SENT sid="8" pm="."><plain>After 13.4 +/- 11.8 months in 17 of 35 patients (8 with SLE, 5 with NS, 4 with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease), <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> was established as the monotherapy </plain></SENT>
<SENT sid="9" pm="."><plain>No severe side effects were registered </plain></SENT>
<SENT sid="10" pm="."><plain>In treating active stages of severe progressive <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> and forms with persistent high antibody levels, the addition of TPE to conventional therapy was very effective, as observed in both clinical and laboratory parameters </plain></SENT>
</text></document>